Pancreatic Cancer Research

ResearcherCentre Hospitalier de l’Université de MontréalActive in the last 2 years

Mustapha Ali Tehfe

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1380-5110; OpenAlex author ID A5071219496. Sources: OpenAlex.

Their work

Papers
8
Trials
0
Grants
0
Labs led
0
Collaborators
37
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 2 papers · 2023: 2 papers · 2024: none · 2025: 1 paper · 2026: 2 papers

Papers 8

  1. DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab in metastatic pancreatic ductal adenocarc… Co-author DOI 10.1038/s41467-026-70120-z↗
  2. Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-26-0793↗
  3. Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial. Co-author DOI 10.1038/s41467-025-60808-z↗
  4. Systemic inflammatory prognostic scores in advanced pancreatic adenocarcinoma. Co-author DOI 10.1038/s41416-023-02214-0↗
  5. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. Co-author DOI 10.1200/jco.22.01134↗
  6. The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal a… Co-author DOI 10.1038/s41467-022-32591-8↗
  7. hENT1 Expression Predicts Response to Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-22-2576↗
  8. nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial. Co-author DOI 10.1007/s12325-016-0327-4↗

Closest collaborators

The 25 strongest of 37 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ravi Ramjeesingh · 6 shared papers, 2022–2026 · strength 0.94
  2. Jennifer Jane Knox · 6 shared papers, 2022–2026 · strength 0.94
  3. Steve Gallinger · 4 shared papers, 2022–2026 · strength 0.61
  4. Faiyaz Notta · 4 shared papers, 2022–2026 · strength 0.61
  5. George Zogopoulos · 4 shared papers, 2022–2026 · strength 0.61
  6. Félix Couture · 4 shared papers, 2016–2026 · strength 0.59
  7. Petr Kavan · 3 shared papers, 2022–2026 · strength 0.54
  8. Sharlene Gill · 3 shared papers, 2022–2026 · strength 0.54
  9. Christina Kim · 3 shared papers, 2022–2026 · strength 0.54
  10. James Thomas Topham · 3 shared papers, 2022–2026 · strength 0.54
  11. Derek J. Jonker · 3 shared papers, 2022–2026 · strength 0.54
  12. David F. Schaeffer · 3 shared papers, 2022–2026 · strength 0.54
  13. Daniel John Renouf · 3 shared papers, 2022–2026 · strength 0.54
  14. Chris J. O’Callaghan · 3 shared papers, 2022–2026 · strength 0.54
  15. Joanna M. Karasinska · 2 shared papers, 2026 · strength 0.42
  16. Sandra Elisabeth Fischer · 3 shared papers, 2022–2025 · strength 0.40
  17. Robert C. Grant · 3 shared papers, 2022–2025 · strength 0.40
  18. Yifan Wang · 3 shared papers, 2022–2025 · strength 0.40
  19. Grainne Mary O'Kane · 3 shared papers, 2022–2025 · strength 0.40
  20. Yoo‐Joung Ko · 2 shared papers, 2022–2026 · strength 0.33
  21. Barbara T. Grünwald · 2 shared papers, 2023–2025 · strength 0.29
  22. Sheron Perera · 2 shared papers, 2022–2025 · strength 0.27
  23. Michael J. Allen · 2 shared papers, 2022–2023 · strength 0.25
  24. James Biagi · 2 shared papers, 2022–2023 · strength 0.25
  25. Spring Holter · 1 shared paper, 2025 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.